• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Amicus Therapeutics Inc. (Amendment)

    2/13/24 4:58:50 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email
    SC 13G/A 1 tv0277-amicustherapeuticsinc.htm SCHEDULE 13G/A amicustherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Amicus Therapeutics Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  03152W109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  03152W109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    505,369

    7.  SOLE DISPOSITIVE POWER

    27,719,528

    8.  SHARED DISPOSITIVE POWER

    772,958

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,492,486

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.72%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Amicus Therapeutics Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    47 Hulfish Street
    Princeton, NJ 08542

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    03152W109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $FOLD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    7/17/2025$108.00Equal-Weight → Overweight
    Morgan Stanley
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    More analyst ratings

    $FOLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

      Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

      8/21/23 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

      PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

      6/14/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

      Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

      5/6/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    SEC Filings

    See more
    • SEC Form S-8 filed by Amicus Therapeutics Inc.

      S-8 - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      6/5/25 4:46:04 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      6/5/25 4:01:43 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

      SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      5/15/25 9:30:38 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Financials

    Live finance-specific insights

    See more
    • Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

      PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.co

      7/21/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

      1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and c

      5/1/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

      PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com

      4/21/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

      PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.co

      7/21/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

      PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). "We are delighted that we will now be able to offer a compelling new treatment option to patients living with late-onset Pompe disease in Japan. We are grateful to the MHLW and to Japan's Pompe community, including the patients, families, and physicians who participated in our clinical studies, for their collaboration," said Bradley Campbell, President and Chief Executive Officer

      6/25/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

      PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve. In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. In PROPEL, 77% of patients (n=95) received enzyme replacement therapy (ERT) with alglucosidase alfa before study entry, with a median ERT duration of 7.4 years. In this new

      6/3/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amicus Therapeutics upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Amicus Therapeutics from Equal-Weight to Overweight and set a new price target of $108.00

      7/17/25 7:51:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously

      12/13/24 7:53:22 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Amicus Therapeutics with a new price target

      Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00

      9/6/24 7:39:36 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mcglynn Margaret G was granted 20,414 shares, increasing direct ownership by 29% to 91,550 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      6/6/25 4:59:48 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Raab Michael was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      6/6/25 4:58:48 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sblendorio Glenn was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      6/6/25 4:58:02 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:00:58 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Amicus Therapeutics Inc.

      SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 11:37:23 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:31:54 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care